Tag
Omission of sentinel lymph node biopsy (SLNB) in select postmenopausal patients with early HR+/HER2- breast cancer and negative axillary ultrasound is feasible and safe, reducing surgical morbidity without compromising short-term outcomes.
In women aged 65 and older with cT2N0 hormone receptor-positive, HER2-negative breast cancer, sentinel lymph node biopsy rarely alters adjuvant therapy plans, supporting a more individualized approach to axillary staging in this population.
This review evaluates whether sentinel lymph node biopsy omission, validated in SOUND and INSEMA trials, applies to cT1N0 invasive lobular carcinoma, highlighting nodal positivity rates, risk factors such as lymphovascular invasion, and cli
This review synthesizes evidence that modern personalized surgical strategies for vulvar squamous cell carcinoma enhance survival outcomes despite higher reoperation rates, emphasizing evolving surgical techniques, sentinel lymph node biops
A recent study demonstrates the feasibility and safety of hybrid indocyanine green and technetium-99m nanoparticle fluorescence imaging for sentinel lymph node biopsy in early-stage vulvar cancer, improving detection rates and oncologic out
Sentinel lymph node biopsy in atypical endometrial hyperplasia patients identifies occult cancers and refines adjuvant treatment strategies, supporting its safe and feasible use for better risk stratification.
The SENTIX study demonstrates that sentinel lymph node biopsy preserves quality of life, reduces lymphoedema incidence, and lowers early postoperative complications compared to pelvic lymphadenectomy in early-stage cervical cancer patients.
A comprehensive cohort study reveals that sentinel lymph node biopsy (SLNB) in head and neck Merkel cell carcinoma has a sensitivity of only 52.6% and a high failure rate. The findings suggest that clinicians must reconsider management stra
This article examines the clinical accuracy of Sentinel Lymph Node Biopsy for head and neck Merkel cell carcinoma, highlighting a significant false-negative rate and identifying risk factors that necessitate more personalized treatment stra
The MERLIN_001 study validates a combined clinicopathological and gene expression profile test that accurately predicts sentinel lymph node metastasis risk in patients with cutaneous melanoma, potentially guiding safer, more personalized su
